AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9774816 — intervention group
Group type: COMPARATOR
Intervention: Primary care referrals
Number of subjects: 954
Study 7523736 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical prostatectomy with early intervention for disease persistence/recurrence
Number of subjects: 2000
Study 7523736 — intervention group
Group type: COMPARATOR
Intervention: Expectant management with palliative therapy reserved for symptomatic or metastatic disease progression
Number of subjects: 2000
Study 3357987 — intervention group
Group type: EXPERIMENTAL
Intervention: Thallium-201 myocardial scintigraphy (M)
Number of subjects: 23
Study 3357987 — intervention group
Group type: COMPARATOR
Intervention: Exercise radionuclide ventriculography (ERV)
Number of subjects: 23
Study 31880084 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous robot‐assisted minimally invasive pedicle screw insertion
Number of subjects: 80
Study 31880084 — intervention group
Group type: COMPARATOR
Intervention: Freehand fluoroscopy‐assisted pedicle screw insertion using a traditional open technique
Number of subjects: 80
Study 29866086 — intervention group
Group type: EXPERIMENTAL
Intervention: HF‐rTMS (10 sessions)
Number of subjects: 80
Study 29866086 — intervention group
Group type: COMPARATOR
Intervention: Placebo/sham HF‐rTMS (10 sessions)
Number of subjects: 80
Study 28107894 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate variability biofeedback therapy (HRV-BF)
Number of subjects: 28
Study 28107894 — intervention group
Group type: COMPARATOR
Intervention: Graded exercise training (GET)
Number of subjects: 28
Study 25160533 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein 10 mg daily for 1 year
Number of subjects: 70
Study 25160533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 22365647 — intervention group
Group type: EXPERIMENTAL
Intervention: B vitamins
Number of subjects: 1863
Study 22365647 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3 PUFA
Number of subjects: 1863
Study 21248246 — intervention group
Group type: EXPERIMENTAL
Intervention: Steerable sheath
Number of subjects: 130
Study 21248246 — intervention group
Group type: COMPARATOR
Intervention: Nonsteerable sheath
Number of subjects: 130
Study 18420965 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine challenges
Number of subjects: 1041
Study 18420965 — intervention group
Group type: EXPERIMENTAL
Intervention: History of hay fever
Number of subjects: 1041
Study 18420965 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory allergy
Number of subjects: 1041
Study 18420965 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent inhaled corticosteroid usage
Number of subjects: 1041
Study 16085300 — intervention group
Group type: EXPERIMENTAL
Intervention: Primitives of Binding framework
Number of subjects: 0
Study 16085300 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflexivity
Number of subjects: 0
Study 16085300 — intervention group
Group type: COMPARATOR
Intervention: Government and Binding
Number of subjects: 0
Study 12832707 — intervention group
Group type: EXPERIMENTAL
Intervention: S100A12 levels in serum and synovial fluid
Number of subjects: 42
Study 12832707 — intervention group
Group type: EXPERIMENTAL
Intervention: S100A12 levels in patients with active arthritis
Number of subjects: 42
Study 12832707 — intervention group
Group type: EXPERIMENTAL
Intervention: S100A12 expression in inflamed synovial tissue
Number of subjects: 42
Study 10596755 — intervention group
Group type: EXPERIMENTAL
Intervention: MEP TAB9 with Montanide ISA720 adjuvant
Number of subjects: 100
Study 8726593 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 0
Study 1758385 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulins (IVIG, 500 mg/kg Sandoglobulin)
Number of subjects: 58
Study 1758385 — intervention group
Group type: COMPARATOR
Intervention: Saline as placebo
Number of subjects: 58
Study 6806473 — intervention group
Group type: EXPERIMENTAL
Intervention: Lack anaesthetic breathing system
Number of subjects: 20
Study 6806473 — intervention group
Group type: COMPARATOR
Intervention: Magill anaesthetic breathing system
Number of subjects: 20
Study 6806473 — intervention group
Group type: COMPARATOR
Intervention: Bain anaesthetic breathing system
Number of subjects: 20
Study 31881702 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g of walnuts per day
Number of subjects: 13
Study 31881702 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 13
Study 28917947 — intervention group
Group type: EXPERIMENTAL
Intervention: High glycemic load meal + caffeine capsules (3mgkg‐1 body weight)
Number of subjects: 10
Study 28917947 — intervention group
Group type: COMPARATOR
Intervention: High glycemic load meal + placebo capsules
Number of subjects: 10
Study 28917947 — intervention group
Group type: COMPARATOR
Intervention: Low glycemic load meal + placebo capsules
Number of subjects: 10
Study 26335088 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing Therapy
Number of subjects: 140
Study 26335088 — intervention group
Group type: COMPARATOR
Intervention: Brief Eclectic Psychotherapy (Cognitive-Behavioral Intervention)
Number of subjects: 140
Study 23245520 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid fixation
Number of subjects: 1125
Study 23245520 — intervention group
Group type: COMPARATOR
Intervention: Nonrigid fixation
Number of subjects: 1125
Study 21346183 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glycemic control
Number of subjects: 2053
Study 21346183 — intervention group
Group type: COMPARATOR
Intervention: Standard glycemic control
Number of subjects: 2053
Study 18454510 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin 800 mg/day plus peginterferon alfa‐2a 180 mug/week
Number of subjects: 141
Study 18454510 — intervention group
Group type: COMPARATOR
Intervention: Ribavirin 400 mg/day plus peginterferon alfa‐2a 180 mug/week
Number of subjects: 141
Study 18454510 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin 800 mg/day (group A)
Number of subjects: 141
Study 18454510 — intervention group
Group type: COMPARATOR
Intervention: Ribavirin 400 mg/day (group B)
Number of subjects: 141
Study 18454510 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 141
Study 16290907 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2b 1.5 microg/kg subcutaneously once weekly plus ribavirin 800-1400 mg/day for 24 weeks
Number of subjects: 235
Study 16290907 — intervention group
Group type: COMPARATOR
Intervention: Historical control (Manns et al., Lancet 2001)
Number of subjects: 235
Study 16290907 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with undetectable serum HCV-RNA at treatment week 4
Number of subjects: 235
Study 16290907 — intervention group
Group type: COMPARATOR
Intervention: Control group (historical)
Number of subjects: 235
Study 12603706 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic group (educational package + mite allergen‐impermeable mattress encasings)
Number of subjects: 696
Study 12603706 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 696
Study 12603706 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic group
Number of subjects: 696
Study 10957824 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppression instructions
Number of subjects: 40
Study 10957824 — intervention group
Group type: COMPARATOR
Intervention: Nonsuppression instructions
Number of subjects: 40
Study 10957824 — intervention group
Group type: EXPERIMENTAL
Intervention: Punishment and worry thought control strategies
Number of subjects: 40
Study 10957824 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction cognitive strategy
Number of subjects: 40
Study 8788532 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐HT1a‐receptor agonist ipsapirone (10 mg)
Number of subjects: 40
Study 8788532 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 2058830 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine
Number of subjects: 100
Study 2058830 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Number of subjects: 100
Study 2058830 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 100
Study 6403706 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg norethindrone + 35 micrograms ethinyl estradiol
Number of subjects: 4
Study 6403706 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethynodiol diacetate and norethindrone
Number of subjects: 4
Study 6403706 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-containing preparation
Number of subjects: 4
Study 6403706 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethindrone or ethynodiol diacetate
Number of subjects: 4
Study 6403706 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel preparation
Number of subjects: 4
Study 3948638 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education modules (up to seven modules) including didactic instruction, skill exercises, and behavioral modification techniques.
Number of subjects: 532
Study 3948638 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 532
Study 29842843 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Selected (SS) recovery
Number of subjects: 14
Study 29842843 — intervention group
Group type: COMPARATOR
Intervention: Externally Regulated (ER) recovery
Number of subjects: 14
Study 28718569 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% potassium hydroxide aqueous solution applied daily to the lesions twice daily for 6 weeks
Number of subjects: 120
Study 28718569 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy with liquid nitrogen, applied weekly for 6 weeks
Number of subjects: 120
Study 23818159 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal intervention including letters, automated phone calls, prompts, and a mailed Fecal Immunochemical Testing (FIT) Kit
Number of subjects: 366
Study 23818159 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 366
Study 22634906 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous vitamin C (500 mg/5 cc) three times a week for 8 weeks
Number of subjects: 60
Study 22634906 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 60
Study 20361911 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertive community treatment (ACT) as part of integrated care
Number of subjects: 120
Study 20361911 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 120
Study 18652921 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal movement counting (testing)
Number of subjects: 0
Study 18652921 — intervention group
Group type: COMPARATOR
Intervention: No testing (control)
Number of subjects: 0
Study 15932822 — intervention group
Group type: EXPERIMENTAL
Intervention: Supracervical hysterectomy (SCH)
Number of subjects: 135
Study 15932822 — intervention group
Group type: EXPERIMENTAL
Intervention: Total abdominal hysterectomy (TAH)
Number of subjects: 135
Study 12891538 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening and eradication for Helicobacter pylori (Hp)
Number of subjects: 20000
Study 12891538 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 20000
Study 12891538 — intervention group
Group type: EXPERIMENTAL
Intervention: Hp-eradicated participants
Number of subjects: 20000
Study 12891538 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall health care consultation
Number of subjects: 20000
Study 10472698 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg bodyweight ketamine racemate before skin incision and 10 micrograms/kg/min ketamine infusion until peritoneum closure, followed by sodium chloride 0.9% as placebo after final skin suture.
Number of subjects: 39
Study 10472698 — intervention group
Group type: COMPARATOR
Intervention: Placebos before skin incision and intraoperatively, followed by 0.5 mg/kg bodyweight ketamine after last skin suture.
Number of subjects: 39
Study 10472698 — intervention group
Group type: COMPARATOR
Intervention: Placebos at all three points of time.
Number of subjects: 39
Study 8557385 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin plus metronidazole
Number of subjects: 79
Study 8557385 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime plus gentamicin plus metronidazole
Number of subjects: 79
Study 8557385 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime
Number of subjects: 79
Study 8557385 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 79
Study 1932765 — intervention group
Group type: EXPERIMENTAL
Intervention: buflomedil (400 mg intravenous perfusion for 4 hours daily for 7 days)
Number of subjects: 20
Study 1932765 — intervention group
Group type: EXPERIMENTAL
Intervention: buflomedil
Number of subjects: 20
Study 1932765 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 7044160 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine
Number of subjects: 165
Study 7044160 — intervention group
Group type: COMPARATOR
Intervention: Co-trimoxazole (high daily dosage regimens)
Number of subjects: 165
Study 30717614 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.4 g/kg)
Number of subjects: 302
Study 30717614 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study 30717614 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined data (Alcohol vs. Placebo)
Number of subjects: 302
Study 27428397 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal immunochemical test (FIT) for nonattendees of reduced-preparation CTC
Number of subjects: 16087
Study 27428397 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal immunochemical test (FIT) for nonattendees of full-preparation CTC
Number of subjects: 16087
Study 27428397 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal immunochemical test (FIT) for nonattendees of OC
Number of subjects: 16087
Study 25210009 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized decision support system
Number of subjects: 21230
Study 25210009 — intervention group
Group type: COMPARATOR
Intervention: Standard software alone
Number of subjects: 21230
Study 25201518 — intervention group
Group type: EXPERIMENTAL
Intervention: Single morning dose of mitotane
Number of subjects: 10
Study 25201518 — intervention group
Group type: COMPARATOR
Intervention: No morning dose of mitotane
Number of subjects: 10
Study 22379738 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E 350 mg daily for 1 month (n = 5)
Number of subjects: 14
Study 22379738 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 1 month (n = 4)
Number of subjects: 14
Study 22379738 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation
Number of subjects: 14
Study 20569710 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg norethindrone/10 microg ethinyl estradiol
Number of subjects: 35
Study 20569710 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 17699816 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation
Number of subjects: 286
Study 17699816 — intervention group
Group type: COMPARATOR
Intervention: No further therapy (control group)
Number of subjects: 286
Study 17038829 — intervention group
Group type: EXPERIMENTAL
Intervention: ChimeriVax‐WN02
Number of subjects: 2
Study 17038829 — intervention group
Group type: COMPARATOR
Intervention: YF‐VAX (licensed yellow fever 17D vaccine)
Number of subjects: 2
Study 11417280 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-layer bandages (4LB)
Number of subjects: 112
Study 11417280 — intervention group
Group type: COMPARATOR
Intervention: Short-stretch bandages (SSB)
Number of subjects: 112
Study 9241098 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS 5 mg
Number of subjects: 12
Study 9241098 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS 10 mg
Number of subjects: 12
Study 9241098 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8106952 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal dressing with 0.2% chlorhexidine mouthwash (10 ml for 1 minute twice daily)
Number of subjects: 24
Study 8106952 — intervention group
Group type: COMPARATOR
Intervention: No periodontal dressing with 0.2% chlorhexidine mouthwash (10 ml for 1 minute twice daily)
Number of subjects: 24
Study 3307404 — intervention group
Group type: EXPERIMENTAL
Intervention: Glipizide
Number of subjects: 15
Study 3307404 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 3307404 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight reduction, exercise, diet, and glipizide therapy
Number of subjects: 15
Study 3307404 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviorally oriented nutrition-exercise program
Number of subjects: 15
Study 3307404 — intervention group
Group type: COMPARATOR
Intervention: Insulin (baseline)
Number of subjects: 15
Study 3307404 — intervention group
Group type: EXPERIMENTAL
Intervention: Eucaloric diet
Number of subjects: 15
Study 31382815 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved PVP
Number of subjects: 44
Study 31382815 — intervention group
Group type: COMPARATOR
Intervention: Traditional PVP
Number of subjects: 44
Study 28786358 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist
Number of subjects: 0
Study 28786358 — intervention group
Group type: COMPARATOR
Intervention: GnRH antagonist
Number of subjects: 0
Study 26521182 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week intervention combining muscle resistance, aerobic and inspiratory pressure load exercises
Number of subjects: 48
Study 23890855 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibetan diet
Number of subjects: 524
Study 23890855 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Western diet)
Number of subjects: 524
Study 21786577 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 30
Study 21786577 — intervention group
Group type: COMPARATOR
Intervention: Dopamine
Number of subjects: 30
Study 19423999 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal microdose 17beta-estradiol (0.014 mg/d)
Number of subjects: 500
Study 19423999 — intervention group
Group type: COMPARATOR
Intervention: Oral raloxifene (60 mg/d)
Number of subjects: 500
Study 16919005 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line bosentan treatment
Number of subjects: 358
Study 14726165 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen plus diesel exhaust particles
Number of subjects: 0
Study 14726165 — intervention group
Group type: COMPARATOR
Intervention: Allergen alone
Number of subjects: 0
Study 11360697 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult hearing screening with audiometric testing at 0.5, 1, 2, 3, and 4 kHz; advice given if average hearing loss exceeded 20 dBHL; noise avoidance emphasized if thresholds exceeded 25 dBHL bilaterally at 4 kHz.
Number of subjects: 0
Study 11360697 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 0
Study 9406128 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonprotein calorie group: dextrose and lipid intake equal to measured energy expenditure
Number of subjects: 0
Study 9406128 — intervention group
Group type: EXPERIMENTAL
Intervention: Total calorie group: dextrose, lipid, and protein intake equal to measured energy expenditure
Number of subjects: 0
Study 9406128 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric group: dextrose and lipid intake equal to 50% of measured energy expenditure
Number of subjects: 0
Study 9406128 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (nonprotein and total calorie)
Number of subjects: 0
Study 8484675 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprascapular nerve block (SSNB) with bupivacaine alone (Ba)
Number of subjects: 29
Study 8484675 — intervention group
Group type: COMPARATOR
Intervention: Suprascapular nerve block (SSNB) with bupivacaine plus methylprednisolone (Ba + P)
Number of subjects: 29
Study 3319646 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone 12.5 mg o.d.
Number of subjects: 75
Study 3319646 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone 25 mg o.d.
Number of subjects: 75
Study 3319646 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone 50 mg o.d.
Number of subjects: 75
Study 3319646 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 28605819 — intervention group
Group type: EXPERIMENTAL
Intervention: Frameless fiducial-less brain biopsy
Number of subjects: 56
Study 28605819 — intervention group
Group type: COMPARATOR
Intervention: Frame-based stereotactic biopsy
Number of subjects: 56
Study 27091318 — intervention group
Group type: EXPERIMENTAL
Intervention: Monosodium glutamate (MSG) 150 mg/kg
Number of subjects: 24
Study 27091318 — intervention group
Group type: COMPARATOR
Intervention: NaCl (control) 24 mg/kg
Number of subjects: 24
Study 25219389 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 73
Study 25219389 — intervention group
Group type: COMPARATOR
Intervention: Algorithm-based pharmacological treatment
Number of subjects: 73
Study 22523120 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message-based smoking cessation intervention
Number of subjects: 2915
Study 21205234 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel plus acetylsalicylic acid
Number of subjects: 4318
Study 21205234 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus acetylsalicylic acid
Number of subjects: 4318
Study 18274692 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline dissemination
Number of subjects: 362
Study 18274692 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline dissemination plus educational session
Number of subjects: 362
Study 18274692 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline dissemination, educational session, plus individualised treatment advice
Number of subjects: 362
Study 16864749 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 18002
Study 16864749 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril
Number of subjects: 18002
Study 14583366 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 8768
Study 11360070 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole 400 mg daily for 7 days (treated partners)
Number of subjects: 144
Study 11360070 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated partners)
Number of subjects: 144